Adial Pharmaceuticals, Inc.
1180 Seminole Trail, Suite 495
Charlottesville, Virginia 22901
July 24, 2018
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, NE
Washington, D.C. 20549
Attention: Suzanne Hayes, Assistant Director
Office of Healthcare & Insurance
|Re:||Adial Pharmaceuticals, Inc.|
|Registration Statement on Form S-1, as amended|
|File No. 333-220368|
Dear Ms. Hayes:
Adial Pharmaceuticals, Inc. (the “Company”) hereby requests that the effective date of the Company’s Registration Statement on Form S-1, as amended (File No. 333-220368), be accelerated by the U.S. Securities and Exchange Commission to Thursday, July 26, 2018 at 5:00 p.m., New York City Time, or as soon as reasonably practicable thereafter.
The Company hereby authorizes its legal counsel, Patrick Egan and/or Leslie Marlow of Gracin & Marlow, LLP, to orally modify or withdraw this request for acceleration. Please contact Mr. Egan at (914) 557-5574 or Ms. Marlow at (516) 496-2223 or (212) 907-6457 with any questions you may have concerning this request, and please notify either of them when this request for acceleration has been granted.
|Very truly yours,|
|Adial Pharmaceuticals, Inc.|
|By:||/s/ William B. Stilley, III|
|Name: William B. Stilley, III|
|Title: Chief Executive Officer|
|Chief Financial Officer, Adial Pharmaceuticals, Inc.|